[1] Mabuchi S, Isohashi F, Yokoi T, et al. A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes[J].Gynecol Oncol,2016, 141(2): 240~246. [2] 焦今文,赵新卫,刁玉超,等.伊立替康联合顺铂新辅助化疗对ⅠB2~ⅡB期宫颈癌的有效性和安全性分析[J].中国医师杂志,2016,18(4):552~556. [3] 赵林,张春林.伊立替康联合顺铂同步放化疗治疗中晚期宫颈癌的疗效对照研究[J].实用临床医药杂志,2013,17(21):122~124. [4] 彭一,林芳.伊立替康在局部晚期宫颈癌患者新辅助化疗中的应用效果[J].实用癌症杂志,2016,31(7):1143~1145. [5] Ji J, Zuo P, Wang Y L. Enhanced antiproliferative effect of carboplatin in cervical cancer cells utilizing folate-grafted polymeric nanoparticles[J].Nanoscale Res Lett,2015, 10(1): 453. [6] 李倩,刘巧玲,武渊,等.伊立替康联合卡铂辅助化疗对宫颈癌患者血清叶酸和CA125水平的影响[J].现代生物医学进展,2016,16(33):6481~6483,6536. [7] 田野,王蕾.伊立替康联合腹腔镜改良切除术对早期宫颈癌患者膀胱、直肠及性功能的改善作用[J].中国药业,2015,24(6):36~37,38. [8] 黄丛秀,宝莹娜,郁志龙等.宫颈癌患者血清SCCCEA表达水平的变化及其临床意义[J].河北医学,2016,22(10):1670~1672. [9] Mabuchi S, Isohashi F, Okazawa M, et al. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients[J].Gynecol Oncol,2017, 28(1): e15. [10] 肖发菊,李金燕.盐酸伊立替康在宫颈癌顺铂方案化疗治疗中的应用效果[J].实用癌症杂志,2016,31(5):808~810,813. [11] 吴航,刘兵,李向辉,等.盐酸伊立替康联合顺铂治疗老年宫颈癌的临床疗效[J].中国老年学杂志,2015(15):4270~4271. [12] Nishio S, Kitagawa R, Shibata T, et al. Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1[J].Cancer Chemother Pharmacol,2016, 78(4): 785~790. [13] 高庆华.盐酸伊立替康联合顺铂方案治疗宫颈癌的效果研究[J].国际病毒学杂志,2015,22(z1):30~32. [14] Sebastiao A M, Da S R L, Gimenez R D, et al. Carboplatin-based chemoradiotherapy in advanced cervical cancer: an alternative to cisplatin-based regimen[J].Eur Obstet Gynecol Reprod Biol,2016, 201: 161~165. [15] 张慧君. 奈达铂或伊立替康联合紫杉醇作为首选方案治疗中晚期宫颈癌的疗效比较[J].实用癌症杂志,2013,28(3):272~274.
2017, Vol. 23 
冀公网安备13080202000677号